Competition in off-patent drug markets: Issues, regulation and evidence

Economic Policy

Volumn 23, Issue 55, 2008, Pages 499-544

  Kanavos, Panos ^a   Costa Font, Joan ^a   Seeley, Elizabeth ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPETITION (ECONOMICS); ECONOMIC POLICY; HEALTH CARE; HEALTH INSURANCE; MARKET DEVELOPMENT; PHARMACEUTICAL INDUSTRY; PRICE DYNAMICS; REGULATORY FRAMEWORK;

EID: 45449095988     PISSN: 02664658     EISSN: 14680327     Source Type: Journal    
DOI: 10.1111/j.1468-0327.2008.00207.x     Document Type: Article

References (83)

1. Anis, A. (1994). 'Substitution laws, insurance coverage, and generic drug use', Medical Care, 32 (3), 240-56.
2. Aronson, T., M. Bergman and N. Rudholm (2001). 'The impact of generic drug on brand name market shares: Evidence from micro data', Review of Industrial Organization, 19, 425-35.
3. Bain, J. (1949). 'A note on pricing monopoly and oligopoly', American Economic Review, 39, 448-64.
4. Baldwin, R. (1997). Rules and Government, London: Oxford University Press.
5. Baltagi, B.H. (2004). Econometric Analysis of Panel Data, New York: John Wiley and Sons.
6. Banahan, B. and E. Kolassa (1997). 'A physician survey on generic drugs and substitution of critical dose medications', Archives of Internal Medicine, 157, 2080-88.
7. Bateman, D., M. Campbell, L. Donaldson, S. Roberts and J. Smith (1996). 'A prescribing incentive scheme for non-fundholding general practices: an observational study', British Medical Journal, 313, 535-38.
8. Bergman, M.A. and N. Rudholm (2003). 'The relative importance of actual and potential competition: Empirical evidence from the pharmaceutical market', The Journal of Industrial Economics, 60, 544-67.
9. Berndt, E.R. (2002). 'Pharmaceuticals in US health care: Determinants of quantity and prices', Journal of Economic Perspectives, 16 (4), 45-66.
10. Blumenthal, D. and R. Herdman (2000). Description and Analysis of the VA National, Washington, DC: National Academy Press Formulary.
11. Busse, R. (2001). 'Interesting times in German health policy', Eurohealth, 7 (2), 7-8.
12. Busse, R. and C. Howorth (1999). 'Cost-containment in Germany 1977-97', in E. Mossialos and J. LeGrand (eds.), Health Care and Cost Containment in the European Union, 303-39, Aldershot: Ashgate.
13. Cage, A. (2001). 'Pharmacists' individual and organizational views on generic medications', Journal of the American Pharmaceutical Association, 41 (5), 723-28.
14. Caves, R.E., M.E. Whinston and M.A. Hurwitz (1991). 'Patent expiration, entry, and competition in the US pharmaceutical industry: An exploratory analysis', Brookings Papers on Economic Activity: Microeconomics, 1-66, Washington: Brookings Institute.
15. CDER (Centre for Drug Evaluation and Research) (1998). 1998 Report to the Nation, Washington, DC: Centre for Drug Evaluation and Research, US Food and Drug Administration.
16. Chaix-Couturier, C., I. Durand-Zaleski, D. Jolly and P. Durieux (2000). 'Effects of financial incentives on medical practice: Results from a systematic review of the literature and methodological issues', International Journal for Quality in Health Care, April, 12 (2), 133-42.
17. Chapman, S., P. Durieux and T., Walley (2004). 'Drug administration and good prescribing practice', in E. Mossialos, M. Mrazek and T. Walley (eds.), Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (Chapter 8), Buckingham: Open University Press.
18. Congressional Budget Office (United States CBO) (1998). How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, Washington: CBO.
19. CDMA (1999). 'Changes to Ontario Formulary will mean big savings for health care system', Viewpoint-News from Canada's National Pharmaceutical Industry, Winter, 3-4.
20. Cool, K., L.H. Röller and B. Leleux (1999). 'The relative impact of actual and potential rivalry on firm profitability in the pharmaceutical industry', Strategic Management Journal, 20, 1-14.
21. Danzon, P.M. (1998), 'The economics of parallel trade', Pharmacoeconomics, 13 (3), 293-303.
22. Danzon, P.M. and L.W. Chao (2000). 'Does regulation drive out competition in pharmaceutical markets?', Journal of Law and Economics, 43 (2), 311-57.
23. Delnoij, D. and G. Brenner (2000). 'Importing budget systems from other countries: What can we learn from the German drug budget and the British GP fundholding?', Health Policy, 52 (3), 157-69.
24. DH (UK Department of Health) (2000). 'Generic drug prices and proposals to set maximum prices for generic medicines', Department of Health.
25. DH (UK Department of Health) (2001). Options for the Future Supply and Reimbursement of Generic Medicines for the NHS, UK Department of Health, July, London.
26. DH (UK Department of Health) (2006). Practice Based Commissioning and Budget Setting, UK Department of Health, Gateway reference 6446, April, London (accessed 4 April 2008: http://www.dh.gov.uk/en/ Managingyourorganisation/Commissioning/Practice-basedcommissioning/ DH_4130824).
27. DHHS (US Department of Health & Human Services) (2000). Prescription Drug Coverage, Spending, Utilization and Prices, Report to the President, DHSS, Washington, DC, April.
28. DKG (1993). Survey by the Germany Hospital Association, DKG (Germany), 17 December.
29. EGA (2004). Data Exclusivity vs Bolar Provision: A False 'Trade-off', EGA Position Paper, European Generic Medicines Association, January.
30. Ellison, S.F., I. Cockburn, Z. Griliches and J. Hausman (1997). 'Characteristics of demand for pharmaceutical products: An examination of four cephalosporins', RAND Journal of Economics, 28 (3), 426-46.
31. Frank, R.G. and D.S. Salkever (1997). 'Generic entry and the pricing of pharmaceuticals', Journal of Economics and Management Strategy, 6 (1), 75-90.
32. Garattini, L. and F. Salvioni (1996). 'Distribution margins: A European overview', Pharma Pricing Review, 1 (8), 154-57.
33. Garattini, L. and F. Tediosi (2000). 'A comparative analysis of generic markets in five European countries', Health Policy, 51, 149-62.
34. Gaynor, M. and S.W. Polachek (1994). 'Measuring information in the market: An application to physicians services', Southern Economic Journal, 60, 815-31.
35. Giuliani, G., G. Selke and L. Garattini (1998). 'The German experience in reference pricing', Health Policy, 44, 73-85.
36. Grabowski, H. and J. Vernon (1986). 'Longer patents for lower imitation barriers: The 1984 Drug Act', American Economic Review, 76 (2), 195-98.
37. Grabowski, H. and J. Vernon (1992). 'Brand loyalty and price competition in pharmaceuticals after the 1984 Drug Act', Journal of Law and Economics, 35 (2), 331-50.
38. Grootendorst, P., L. Dolovich, B. O'Brien, A. Holbrook and A. Levy (2001). 'Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs', Canadian Medical Association Journal, 165 (8), 1011-19.
39. Harris, C.M. and G. Scrivener (1996). 'Fundholders' prescribing costs: the first five years', British Medical Journal, 313, 1531-34.
40. Himmel, W., M. Kron, S. Thies-Zajonc and M. Kochen (1997). 'Changes in drug prescribing under the Public Health Reform Law -a survey of general practitioners' attitudes in East and West Germany', International Journal of Clinical Pharmacology and Therapeutics, 35 (4), 164-68.
41. Hollis, A. (2002). 'The importance of being the first: Evidence from Canadian generic pharmaceuticals', Health Economics, 11 (8), 723-34.
42. Huttin, C. (1996). 'A critical review of the remuneration system for pharmacists', Health Policy, 36, 53 D -68.
43. Jones, J.C.H., T. Potashnik and A. Zhang (2001). 'Patents, brand generic competition and the pricing of ethical drugs in Canada: Some empirical evidence form British Columbia 1981-1994', Applied Economics, 33, 947-56.
44. Jönsson, B. (1994). 'Pricing and reimbursement of pharmaceuticals in Sweden', Pharmacoeconomics, 6, Suppl 1, 51-60.
45. Kanavos, P. (2002a). Pharmaceutical Pricing and Reimbursement in Europe, PJB Publications, May.
46. Kanavos, P. (2002b). 'Pharmaceutical purchasing at state and federal levels in the US', in Academy of Health Services Research and Health Policy Annual Meeting, 23 June, Washington, DC.
47. Kanavos, P. (2007). 'Do generics offer significant savings to the UK National Health Service', Current Medical Research and Opinion, 23 (1), 105-16.
48. Kanavos, P., J. Costa Font and A.J. McGuire (2007). 'Product differentiation, competition and regulation of new drugs: The case of statins in four European countries', Managerial and Decision Economics, 28, 455-65.
49. Kanavos, P. and M.C. Gemmill (2005). Pharmaceutical Pricing and Reimbursement in Europe, London: Informa Publishing, August.
50. Kanavos, P. and E. Mossialos (1999). 'International comparisons of health care expenditures: What we know and what we do not know', Journal of Health Services Research and Policy, April, 4 (2), 122-26.
51. Kanavos, P. and U. Reinhardt (2003). 'Reference pricing for drugs: Is it compatible with US health care?', Health Affairs (Milwood), May-June, 22 (3), 16-30.
52. Kanavos, P. and D. Srivastava (2007). 'The impact of patent expiry on product competition and generic market entry: Evidence on ACE inhibitors from 4 European countries', EUROPEAN Journal of Health Economics, under review.
53. King, D.R. and P. Kanavos (2002). 'Encouraging the use of generic medicines: Implications for transition economies', Croatian Medical Journal, 43 (4), 462-69.
54. Kjoenniksen, I., M. Lindbaek and A. Granas (2006). 'Patients' attitudes towards and experiences of generic drug substitution in Norway', Pharmacy World and Science, 28 (5), October, 284-89(6).
55. Lexchin, J. (2004). 'The effect of generic competition on the price of brand name drugs', Health Policy, 68 (1), 47-54.
56. Lopez-Casasnovas, G. and J. Puig-Junoy (2000). 'Review of the literature on reference pricing', Health Policy, 54, 87-123.
57. Mossialos, E. (1997). 'An evaluation of the PPRS: Is there a need for reform', in D. Green (ed.), Should Pharmaceutical Prices Be Regulated, London: IEA.
58. Mossialos, E.A., A. Dixon, J. Figueras and J. Kutzin (2002). Funding Health Care: Options for Europe, Buckingham: Open University Press.
59. Mrazek, M.F. and R. Frank (2004). 'The off-patent pharmaceutical market', in E. Mossialos, M. Mrazek and T. Walley (eds.), Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality, Buckingham: Open University Press.
60. Mrazek, M. and E.A. Mossialos (2000). 'Increasing demand while decreasing costs of generic medicines', The Lancet, 356 (9244), 1784-85.
61. Muller, H. (1994). 'GSG und die Auswirkungen in der Arztpraxis: Schwarzeck-Gerlag', GmbH.
62. NERA (1998). 'Policy related to generic medicines in the OECD', National Economic Research Associates, December.
63. OEBIG (2006). 'Pharmaceutical pricing and reimbursement in the European Union'. Vienna.
64. OXERA (2001). 'Fundamental review of the generic drugs market', Oxford Economic Research Associates, July.
65. Reekie, W.D. (1998). 'How competition lowers the costs of medicines', Pharmacoeconomics, 14 (Suppl.1), 107-13.
66. Reiffen, D. and M. Ward (2005). 'Generic entry industry dynamics', The Review of Economics and Statistics, 87 (1), 37-49.
67. Rizzo, J.A. and R. Zeckhauser (2005). 'Generic scrip and the price of brand name drugs: The role of consumer choice', NBER Working Paper Series, 11431.
68. Rovira, J. and J. Darbà(2001). 'Pharmaceutical pricing and reimbursement in Spain', HEPAC, 2, 39-43.
69. Sansgiry, S., M. Bhosle and N. Pope (2006). 'Consumer perceptions regarding generic drug substitution: An exploratory study'. Journal of Pharmaceutical Marketing & Management, 17 (1), 77-93.
70. Schoffski, O. (1996). 'Consequences of implementing a drug budget for office-based physicians in Germany', Pharmacoeconomics, 10 (2), 37-47.
71. Scott-Morton, F.M. (1999). 'Entry decision in the generic pharmaceutical industry', Rand Journal of Economics, 30, 421-40.
72. Simoens, S., and S. de Coster (2006). Sustaining Generic Medicines Markets in Europe, April, Leuven, Belgium: Katholieke Universiteit Leuven.
73. Sloan, F., K. Whetten-Goldstein and A. Wilson (1997). 'Hospital pharmacy decisions, cost containment and the use of cost-effectiveness analysis', Social Science and Medicine, 45 (4), 523-33.
74. Stackelberg, H. (1952). The Theory of the Market Economy (trans. Alan T. Peacock), 194-204, New York: Oxford University Press.
75. Strollo, M. (1999). 'Managed care and generic pharmaceuticals', in IGPA Conference, Barcelona, Spain, June.
76. Suh, D.C., S. Schondelmeyer, W. Manning, R. Hadsall and J. Nyman (1999). 'Price trends before and after patent expiration in the pharmaceutical industry', Journal of Research in Pharmaceutical Economics, 9 (2), 17-32.
77. Tirole, J. (1988). The Theory of Industrial Organization, Boston, MA: MIT Press.
78. Walley, T. and E. Mossialos (2004). 'Financial incentives and prescribing', in E. Mossialos, M. Mrazek, and T. Walley (eds.), Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality, Chapter 10, Buckingham: Open University Press.
79. Wang, Y.R. (2006). 'Price competition in the Chinese pharmaceutical market', International Journal of Health Care Finance and Economics, 6, 119-29.
80. Whynes, D., D. Baines and K. Tolley (1997). 'GP fundholding and the costs of prescribing: Further results', Journal of Public Health Medicine, 19 (1), 18-22.
81. Wiggins, S.N. and R.S. Maness (2004). 'Price competition in pharmaceuticals: The case of anti-infectives', Economic Inquiry, 42, 247-62.
82. Wilson, R., I. Buchan and T. Walley (1995). 'Alterations in prescribing by general practitioner fundholders: An observational study', British Medical Journal, 311, 1347-50.
83. Young, J. (1994). 'Prescribing generic drugs', British Journal of General Practice, 44 (380), 139-40.